How predictive is PK/PD ?. Niels FrimodtMøller, MD DrSci Microbiological R & D Antibiotic Resistance Surveillance Unit Statens Serum Institut Copenhagen, Denmark. NFM 2001. Pharmacodynamic parameters. Pharmacokinetic parameters: Peak/MIC ratio AUC/MIC ratio Time > MIC
Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.
Niels FrimodtMøller, MD DrSci
Microbiological R & D
Antibiotic Resistance Surveillance Unit
Statens Serum Institut
Copenhagen, Denmark
NFM 2001
(minimal bactericidal concentration (MBC) (time kill activity)
MIC
NFM 2001
Timedependent, concentration
independent:
Betalactams
Macrolides
Tmp/sulfa
Glycopeptides

Concentration dependent:
Aminoglycosides
Fluoroquinolones
Streptogramins


Pharmacodynamics as related to timekill activity in vitro/in vivoNFM 2001
Bacterial growth curve
Peak,a
Peak,b
MIC
Tmax,a
Tmax,b
AUC/MIC,a = AUC/MIC,b
Peak,a = Peak,b
NFM 2001
NFM 2001
1) linearly increasing resistance levels
e.g. PBP changes in pneumococci,
stepwise gyrA mutations
2) resistance mechanisms expressed in whole
bacterial population
e.g. TEM1 betalactamase in E. coli
sulI and sulII in Enterobacteriaceae
NFM 2001
e.g. vanB in E.faecium, certain erm genes
NFM 2001
Steven C. Ebert
Handbook of Pharmacokinetic/Pharmacodynamic Correlation, CRC Press 1995
NFM 2001
Log ED50 mg/mouse
100
10
1
Log MIC
mg/l
0.01
0.1
1
10
Knudsen et.al. AAC 1995;39:125358.
NFM 2001
Knudsen et.al. AAC 1995;39:125358.
NFM 2001
2.5
0.0
Change in log CFU
2.5
5.0
8
4
16
2
0
5
10
15
20
MIC (mg/l)
NFM 2001
Effect of penicillin on S. pneumoniae infection in treated with CEFPROZIL for 24 h.peritoneum (P), thigh (TH) and lung (L) of miceErlendsdottir et.al. AAC, 2001, 45: 107885.
Change in CFU
MIC = 1 mg/L
Th
P
L
Th P L
Th P L
Th P L
Th P L
Peak/MIC
T>MIC
7,4 x
13 %
3,7 x
16 %
105 x
65 %
47 x
71 %
15 x
100 %
NFM 2001
Generation time,min
Yellow = mouse lung model
Erlendsdottir et.al., AAC, 2001, 45: 107885
NFM 2001
Dose response experiment in mouseperitonitis model: S.pneumoniae D39 and mutant,D39T6(D39T6 = D39 transformed with mosaic pbp2B gene from highly PRP)
NFM 200001
Dose response experiment in mouseperitonitis model: S.pneumoniae D39 and mutant,D39T6(D39T6 = D39 transformed with mosaic pbp2B gene from highly PRP)
NFM 200001
* IC50, nmol/ml
NFM 2001
Multiple regr.
ED50 vs. MIC, PBP1a,1b,2a, 2b, 3 : logPBp3 only, p=0.0078
cefsulodin
cefalexin
cefoxitin
cefalothin
cefadroxil
cefotaxime
cefaloridin
Williamson et.al. AAC 1980, 18:62937; FrimodtMøller et.al JID 1986,154: 51117
NFM 2001
LogED50,
mg/kg
2
1,5
1
0,5
0
0,5
Cefepime
1,5 1 0,5 0 0,5 1 1,5
Log MIC, mg/L
Knudsen et.al. JAC 40: 679, 1997
NFM 2001
NB: NCCLS breakpoint < 4 mg/l
NFM/2001
NFM 2001
Cure was best predicted by the time the SePenicillin Conc. remained above 34 x MIC; those cured had SePenicillin Conc. in this range for 710 h.
NFM 2001
Treatment failure (%)
N= 833
341
329
343
3.4
8.8
3.0
1.7
2 g po
2 g po +
probenecid
1 g x 2 with
5 h interval
PcG
2.2 MIU i.m.
Ampicillin
NFM 2001
NFM 2001
* mean, units/ml
P = NS
NFM 2001
Bacte
riolo
gic
cure
(%)
Time > MIC (% of dosing interval)
NFM 2001
NFM 2001
NFM 2001
NFM 2001
NFM 2001
NFM 2001
Continuous vs. Intermittent infusion of oxacillin in patients with staphylococcal infectionsRaber et.al. 36th ICAAC 1996 Abst, No. A104
a)
a)
Same effect in the two treatment groups
NFM 2001
Experimental UTI in mice with E. coli patients with staphylococcal infections
4 days treatment BID with 5 betalactams
NFM 2001
Experimental UTI in mice: patients with staphylococcal infections
Pharmacodynamics of Betalactams
NFM 2001
Age > 14 years
Female : male ratio > 4:1
Uncomplicated, symptomatic UTI
Urine culture before (> 100.000 cfu/ml) and
after (410 days) = bacteriological cure(%)
1)Susceptible – E. coli 2) all
Normal renal function
No attempts on localization studies e.g. abcoatedbact.
NFM 2001
Only female patients patients with staphylococcal infections:
Charlton et.al. 1976
Eriksson et.al. 1981
Hoover et.al. 1982
Sutton et.al. 1983
Sigurdsson et.al. 1983
Kleinschmidt et.al. 1983
Morgan et.al. 1984
McAllister et.al. 1984
Nicolle et.al. 1993
Whitby et.al. 1993
Masterton et.al. 1995
Female and male patients:
Grüneberg et.al. 1967
Bresky 1977
Grob et.al. 1977
Rotschafer et.al. 1979
Leigh et.al. 1980
Iravani et.al. 1988
17 studies,
20 treatment groups with aminopenicillins
Aminopenicillins for uncomplicated UTI:Literature studyNFM 2001
T>MIC = (ln (dose/Vd /fu) – ln MIC)/(0.693/T½)
Vd = distribution vol. (amox 0,26 l/kg, ampi 0,24 l/kg)
Patient weight = 60 kg
fu = degree nonproteinbound (83%)
T½ = 1 h
MIC = 8 mg/l
NFM 2001
No. of strains
MIC, mg/l
NFM 2001
NFM 2001
NFM 2001
NFM 2001 patients with staphylococcal infections
NFM 2001
Ciprofloxacin vs. Pondocillin for epididymitis in men > 40 years (prosp,rand,db): N=55 E. coliEickhoff et.al. Brit J Urol 1999, 84: 827834
P = 0.001
NFM 2001
Optimal time > MIC – const. infus
Intermittent dosing > 50% interval
Intermittent dosing < 50% interval
Bact./ml
Control
Time
NFM 2001
NFM 2001
P < .01
NFM 2001
Response rate, %
Maximum Peak/MIC ratio
NFM 2001
NFM 2001
ratio > 10/1
ratio < 10/1
NFM 2001
NFM 2001
* P < 0.005; ** P<0.001
NFM 2001
NFM 2001
NFM 2001
24 – 48 h predictive of good effect
NFM 2001
NFM 2001